Skip to main content

Biomedical Technologies


Biomedical technologies are shaping the future of life sciences.
From rapid technological advancements to complex regulatory requirements, we know the impact you’re making doesn’t come without challenges. With over 30 years supporting clients in this sector, we’ll help clear the obstacles to build a better tomorrow.
Fasken
Share
  • LinkedIn

Overview

It's an exciting time for the biomedical industry. With the rapid integration of technology, AI and machine learning, developments in genomics, biomarkers and data analysis, and increased demand for sustainable health solutions, the opportunities to make an impact feel limitless. Those businesses that thrive will be the ones who can adapt, navigate the rules and regulations and set the right business strategy from the get go. We can help.

For the last two decades, we’ve played a pivotal role in the life sciences and technology sectors supporting the legal needs of companies driving progress to enhance the quality of life of millions of people around the world.

 We have clients in all sectors including medical devices, natural health products (NHP), cosmetics, cannabis, veterinary and human tissues and advise in all key areas from artificial intelligence, diagnostics and therapeutics to genetics and precision medicine.

Whether you’re a biotech start-up or a large pharmaceutical we have the experience to support you with whatever challenge you might be facing.

Protecting your most important asset

From concept to market, we help structure IP strategy to protect, maximize and enforce your rights. Our IP professionals across Canada act as one multidisciplinary team providing seamless support with the varying federal and provincial rules and regulations. Many of our lawyers have advanced PhD and Master degrees in STEM fields such as pharmaceutical sciences, endocrinology and genetics, immunology, molecular biology, physics and bioengineering. And should you need help enforcing your rights, our patent and IP litigation team our team is standing out for its numerous important victories.

Support from startup to scale-up

As the first Canadian law firm to launch an emerging tech practice over 30 years ago, we’ve helped thousands of startups commercialize their businesses and move on to even bigger successes. Each of our offices offers robust startup programs, allowing us to support early-stage biomedical technology clients with corporate structuring, early-stage financings and scaling as they grow.

We’re deeply involved in the startup ecosystem partnering with some of the most prominent incubators and accelerators, universities and private/public research programs in North America. We leverage our network to ensure you are connected to leading service providers such as Canadian Scientific Research & Experimental Development (SR&ED) program consultants,  accounting firms and major schedule 1 banks.

Mergers & Acquisitions

The trajectory of many venture capital funded technology companies is a successful M&A. We advise buyers, sellers, founders, key shareholders and special committees through this process. We have experience with large and complex cross-border transactions and with varied deal structures, including equity rollovers, exchangeable shares, and hybrid asset/share sales.

Regulatory affairs in life sciences

Our unique skills will be your advantage. Our team is comprised of professionals with advanced scientific degrees and in-house experience at international drug and medical device companies.

We advise on the regulatory aspects of each product development stage from clinical development through to approval and commercialization. We have expertise in clinical trials, market authorization, pricing and reimbursement, post-market vigilance, advertising and promotion, product claims and labeling, quality management and ethical industry standards.  We also negotiate and draft related commercial agreements, and advise on how regulatory considerations should be factored into investment, funding or other opportunities.

Team

Primary Contacts
  • Timothy M. Squire, Partner | CO-LEADER, LIFE SCIENCES, Toronto, ON, +1 416 868 3462, tsquire@fasken.com
  • Mathieu Gagné, Partner | Co-Leader, Life Sciences, Montréal, QC, +1 514 397 7657, mgagne@fasken.com
  • David Turgeon, PhD, Partner | Patent Agent | Leader, Intellectual Property, Montréal, QC | Québec, QC, +1 514 397 5222, dturgeon@fasken.com
  • Will Shaw, Partner | Co-leader, Technology, Media and Telecommunications and Co-leader, Emerging Technology, Toronto, ON, +1 416 865 4554, wshaw@fasken.com
  • Roger A.C. Kuypers, Partner | Trademark Agent, Vancouver, BC, +1 604 631 4880, rkuypers@fasken.com

Client Work

  • Dimension Capital leads Aspect Biosystems in raising US$115 million series B financing to advance bioprinted tissue therapeutics, [Deal - Dimension Capital], US$115 million series B financing in biotech industry
  • Ability Biologics closes its US$18 million seed funding round, [Deal - Ability Biologics], Ability Biologics closes seed funding round.
  • Koble Care Inc. completes asset sale to Dialogue Health Technologies Inc., [Deal - Koble Care Inc.], Canada's premier virtual healthcare and wellness platform invests in digital platform supporting women's health.
  • HEALWELL AI Inc. completes acquisition of Intrahealth Systems Limited, [Deal - HEALWELL AI Inc.], HEALWELL AI Inc. completes acquisition of Intrahealth Systems Limited.
  • SandboxAQ Acquires Good Chemistry, Melding AI and Quantum Tech for Drug Discovery, [Deal - Good Chemistry Inc.], Acquisition in the AI simulation industry
  • Theratechnologies completes a US$25 million cross-border public offering and concurrent private placement with an innovative capital structure component, [Deal - Theratechnologies], Public offering of common shares and concurrent private placement completed by Theratechnologies.
  • Tech company in the healthcare industry completes Series 1 Class Seed Preferred share financing, [Deal - Confidential], Series 1 Class Seed Preferred share financing for tech company
  • Sygnature Discovery acquires NuChem Sciences, [Deal - NuChem Sciences inc.], Sygnature Discovery acquires NuChem Sciences
  • Ditch Labs secures C$ 3.25 million in seed funding, [Case - Ditch Labs], Seed funding for Ditch Labs to help treat nicotine addiction with technology.